We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of Nasal Hair on Nasal Obstruction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01850511
Recruitment Status : Completed
First Posted : May 9, 2013
Last Update Posted : January 22, 2014
Information provided by (Responsible Party):
David (Dave) G. Stoddard, Jr., M.D., Mayo Clinic

Brief Summary:
Nasal obstruction is a common complaint prompting presentation to an otolaryngologist. Many studies have been performed quantifying and describing the impact of a number of factors on symptoms of nasal obstruction, including anatomical, neoplastic, infectious, and inflammatory causes. Despite this scrutiny, no attention has been paid to the nasal vibrissae as a potential anatomical contributor to nasal obstruction. The proposed study intends to elucidate that contribution, if any exists.

Condition or disease Intervention/treatment
Nasal Obstruction Procedure: Vibrissae trimming Drug: Application of oxymetazoline

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction
Study Start Date : May 2013
Primary Completion Date : October 2013
Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Vibrissae trimming
Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
Procedure: Vibrissae trimming
Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
Drug: Application of oxymetazoline
Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
Other Name: Afrin

Primary Outcome Measures :
  1. Nasal airflow/pressure [ Time Frame: Participants will undergo assessment over a 30 minute period, no follow-up ]
    Objective measures include airflow and pressure as assessed by Rhinomanometry.

  2. Subjective Nasal Obstruction [ Time Frame: Participants will undergo assessment over a 30 minute period, no follow-up ]
    Subjective measures will be assessed via the modified version of the NOSE outcome instrument-a validated test of subjective nasal obstruction

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Presence of nasal vibrissae
  • Able to tolerate rhinomanometry

Exclusion Criteria:

  • Anatomical or other obvious cause of obstruction
  • Claustrophobia with rhinomanometry mask

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01850511

United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Grant Hamilton, MD Mayo Clinic

Responsible Party: David (Dave) G. Stoddard, Jr., M.D., Resident Physician, Department of Otolaryngology, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01850511     History of Changes
Other Study ID Numbers: 12-001362
First Posted: May 9, 2013    Key Record Dates
Last Update Posted: January 22, 2014
Last Verified: January 2014

Keywords provided by David (Dave) G. Stoddard, Jr., M.D., Mayo Clinic:
Nasal obstruction
Nasal hair

Additional relevant MeSH terms:
Nasal Obstruction
Nose Diseases
Respiratory Tract Diseases
Airway Obstruction
Respiratory Insufficiency
Respiration Disorders
Otorhinolaryngologic Diseases
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents
Cardiotonic Agents
Adrenergic alpha-1 Receptor Agonists
Protective Agents